AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Immunovia

Board/Management Information May 6, 2023

3061_rns_2023-05-06_1124df3e-d4e5-4d38-80bb-e1a7d80cfac4.pdf

Board/Management Information

Open in Viewer

Opens in native device viewer

PRESS RELEASE

May 6, 2023, Lund, Sweden

The board member Philipp von Hugo resigns from Immunovia's board at his own request

LUND (SWEDEN) – Philipp von Hugo, member of the board of directors of Immunovia AB (publ) ("Immunovia" or the "Company"), has at his own request notified his resignation from the Board of Directors of the Company and therefore declines re-election at annual general meeting on 26 May 2023.

Philipp von Hugo, who has served as board member of Immunovia since the annual general meeting in 2022, has on 5 May 2023 at his own request with immediate effect, notified his resignation from his position as board member of Immunovia and consequently declines reelection, at the annual general meeting on 26 May 2023.

The Nomination Committee of the Company has been informed of his decision. "We thank Philipp for his commitment to the board and wish him the best in his future engagements", comments the chair of the Board of Directors Carl Borrebaeck.

FOR MORE INFORMATION, PLEASE CONTACT:

Carl Borrebaeck Chair of the Board of Directors [email protected] +46 70 821 83 30

Karin Almqvist Liwendahl Chief Financial Officer [email protected] +46 709 11 56 08

ABOUT IMMUNOVIA

Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer. The company is headquartered in Lund, Sweden. Immunovia's shares are listed on Nasdaq Stockholm. For more information please visit www.immunovia.com.

Talk to a Data Expert

Have a question? We'll get back to you promptly.